DisperSol and Catalent Announce Manufacturing Collaboration
DisperSol and Catalent announce manufacturing collaboration to accelerate DisperSol’s pharmaceutical production.
On August 2, 2021, DisperSol Technologies and Catalent announced a strategic manufacturing collaboration aimed at accelerating the production of various DisperSol pharmaceutical products.
DisperSol’s KinetiSol technology manufacturing line will be installed at Catalent's oral solids development and manufacturing facility in Somerset, NJ. This technology is designed to turn molecules with great clinical promise but poor bioavailability into viable medicine.
Per the agreement, DisperSol will provide the KinetiSol technology while Catalent will provide staff for the development, scale-up, and commercial stages of KinetiSol product creation.
“This strategic collaboration with Catalent is integral to our company as we now move into late clinical-stage development and commercial-scale manufacturing of our products,” said DisperSol CEO Edward M. Rudnic in a press release. “The commercial amorphous solid dispersion manufacturing expertise of Catalent’s team and their globally accredited quality systems make them a perfect partner for DisperSol.”
Source: Catalent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
